Results 61 to 70 of about 15,210 (229)

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]

, 2017
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello, Mazzone, Roberta, Valente, Sergio, Zwergel, Clemens   +3 more
core   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway [PDF]

, 2018
Mutations in KIT and TET2 are associated with myeloid malignancies. We show that loss of TET2-induced PI3K activation and -increased proliferation is rescued by targeting the p110α/δ subunits of PI3K.
Gerbaulet, A, Janga, SC, Kapur, R, Mali, RS, Paczesny, S, Palam, LR, Ramdas, B, Roers, A, Srivatsan, SN, Takemoto, CM, Tiu, RV, Vanhaesebroeck, B, Visconte, V, Xu, M   +13 more
core   +1 more source

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick, Margaretha A. Skowron, Gereon Poschmann, Patrick Petzsch, Ann Kathrin Bergmann, Kai Stühler, Jochen Hecht, Daniel Nettersheim   +7 more
wiley   +1 more source

Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes [PDF]

Seminars in Oncology, 2011
Hypomethylating agents such as 5-azacytidine or decitabine have been a major breakthrough in the treatment of patients with myelodysplastic syndromes (MDS). They have been shown to improve transfusion requirements and to change the natural history of the disease. However, with increasing cumulative clinical experience, it has become apparent that these
Tapan M, Kadia, Elias, Jabbour, Hagop, Kantarjian   +2 more
openaire   +2 more sources

Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience

Clinical Case Reports, 2022
We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%.
Alicia Roldán Pérez, Juan Andrés Vázquez Paganini, M. José Penalva Moreno, Eugenio Giménez Mesa, Alba Sara Vilches Moreno, Claudia Nuñez‐Torrón Stock, Regina Herráez García   +6 more
doaj   +1 more source

Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. [PDF]

, 2014
BackgroundSince tumor suppressor gene function may be lost through hypermethylation, we assessed whether the demethylating agent decitabine could increase tumor suppressor gene expression clinically.
Aldaz, Marcelo, Gupta, Sanjay, Hong, David, Issa, Jean-Pierre, Jelinek, Jaroslav, Kurzrock, Razelle, Nunez, Maria I, Stewart, David J, Wistuba, Ignacio I   +8 more
core   +3 more sources

High frequency of CD95+/CD45RA− regulatory T cells defines an immunosuppressive profile associated with MDS progression

British Journal of Haematology, EarlyView.
Summary Dynamic interactions between mutated haematopoietic cells and immune cells are key drivers of myelodysplastic neoplasms (MDS) initiation and progression. Regulatory T cells (Tregs) are central mediators of immunosuppression in MDS. We thus aimed to characterize Treg subpopulations in the bone marrow (BM) of MDS patients and to explore their ...
Romain Vazquez, Nicolas Deredec, Ismael Boussaid, Pierre Boncoeur, Camille Knosp, Amandine Houvert, Loria Zalmai, Chloe Friedrich, Carole Almire, Charles Dussiau, Lise Willems, Rudy Birsen, Justine Decroocq, Didier Bouscary, Olivier Kosmider, Shahram Kordasti, Michaela Fontenay, Yannick Simoni, Nicolas Chapuis   +18 more
wiley   +1 more source

Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes [PDF]

Journal of Clinical Oncology, 2011
Over the last decade, treatment approaches for patients with myelodysplastic syndromes (MDS) have improved significantly. Treatment of MDS is tailored to the specific risk characteristics of the patient. In general, patients are divided into lower- and higher-risk categories.
Guillermo, Garcia-Manero, Pierre, Fenaux
openaire   +2 more sources

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine

Endocrine Oncology, 2023
Downregulation of tumor suppression genes by DNA hypermethylation has been proposed as a potential cause of neuroendocrine neoplasm (NEN) formation. In this report, we present a patient simultaneously diagnosed with acute myeloid leukemia (AML) and a ...
Syed Ehsanullah, Nikolaos A Trikalinos
doaj   +1 more source